[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"University of Split, School of Medicine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":314},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,47,75,94,113,142,162,191,223,243,264,294],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053922","skin-barrier-function-in-women-using-uv-nail-lamps-100053922",false,"NCT07700186","Skin Barrier Function in Women Using UV Nail Lamps","Comparison of Objective Skin Barrier Function Parameters Between Women Who Use and Women Who Do Not Use UV Nail Lamps for Nail Treatments","Inclusion Criteria:\n\n* Healthy adult women (≥18 years of age)\n* Willing and able to provide written informed consent\n* Willing to complete the study questionnaire\n\nExclusion Criteria:\n\n* Active skin diseases (e.g., psoriasis, vitiligo, or other dermatological conditions)\n* Allergic contact dermatitis\n* Pregnancy or breastfeeding\n* Use of topical or systemic corticosteroids, immunosuppressive drugs, or antihistamines",true,"FEMALE","18 Years","50 Years",{"count":21,"type":22},30,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to compare objective parameters of skin barrier function between healthy adult women who regularly use UV lamps during nail treatments and women who do not use UV lamps.\n\nThe main questions it aims to answer are:\n\n* Do women who regularly use UV lamps for nail treatments show differences in skin barrier function compared to women who do not use UV lamps?\n* Are transepidermal water loss, skin hydration, and erythema associated with regular exposure to UV lamps used for nail treatments?\n* Does the duration of UV lamp use influence skin barrier function parameters?\n\nResearchers will compare women who regularly use UV lamps during nail treatments with women who have natural nails and do not regularly expose their hands to UV lamps.\n\nParticipants will:\n\n* Attend a single study visit.\n* Complete a short questionnaire regarding nail care habits and duration of UV lamp use.\n* Undergo non-invasive measurements of skin barrier function on the hands, including transepidermal water loss, skin hydration, and erythema assessments.",[26],"Effects of UV Nail Lamps on Skin Barrier Function",[28,29,30,31,32,33],"UV nail lamps","Gel manicure","Skin barrier function","Transepidermal water loss (TEWL)","Skin hydration","Erythema","RECRUITING","2026-07-07",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-07",{"date":42,"type":22},"2027-07",{"name":44,"class":45},"University of Split, School of Medicine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":19,"enrollmentInfo":55,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":46},"100644953","helichrysum-italicum-extract-in-irritant-contact-dermatitis-100644953","NCT07676253","Helichrysum Italicum Extract in Irritant Contact Dermatitis","Assessment of the Effect of Helichrysum Italicum Extract in Irritant Contact Dermatitis: A Randomized Controlled Clinical Trial","Inclusion Criteria:\n\n* healthy volunteers who gave written informed consent\n\nExclusion Criteria:\n\n* skin disease\n* skin damage on measurement sites\n* use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial\n* pregnancy or breastfeeding\n* immunosuppression\n* allergic or irritant reactions to the constituents of the cream","ALL",{"count":21,"type":22},"INTERVENTIONAL",[58],"NA","The goal of this clinical trial is to evaluate the efficacy and safety of a topical cream containing Immortelle (Helichrysum italicum) extract in promoting skin barrier recovery and reducing signs of irritant contact dermatitis in healthy adult participants.\n\nThe main questions it aims to answer are:\n\n* Does topical application of Helichrysum italicum extract improve skin barrier recovery following experimentally induced irritant contact dermatitis?\n* Does the cream containing Helichrysum italicum extract reduce transepidermal water loss and erythema, and improve skin hydration compared to a standard moisturizing cream?\n* Is the topical application of Helichrysum italicum extract safe and well tolerated?\n\nResearchers will compare skin sites treated with a cream containing Helichrysum italicum extract, placebo-treated skin sites, and untreated skin sites to determine whether the addition of the extract provides additional benefits in skin barrier recovery.\n\nParticipants will:\n\n* Undergo induction of irritant contact dermatitis using sodium lauryl sulfate (SLS) under occlusion.\n* Apply a cream containing Helichrysum italicum extract to one designated skin site and a placebo cream to another designated skin site twice daily throughout the study period.\n* Have an additional SLS-treated skin site left untreated to assess natural skin barrier recovery.\n* Apply the cream containing Helichrysum italicum extract to a separate area of healthy, intact skin.\n* Attend daily study visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema measurements.",[61],"Skin Barrier Disruption and Recovery",[63,64,65,66],"Helichrysum italicum","Immortelle","Irritant contact dermatitis","Skin barrier recovery","2026-06-23",{"date":69,"type":38},"2026-06-30",{"date":71,"type":22},"2026-06",{"date":73,"type":22},"2027-06",{"name":44,"class":45},{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":19,"enrollmentInfo":82,"targetDuration":4,"studyType":56,"phases":83,"briefSummary":84,"conditions":85,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":46},"100641956","evaluation-of-a-peptide-cream-on-the-forearm-skin-recovery-of-healthy-volunteers-100641956","NCT07614698","Evaluation of a Peptide Cream on the Forearm Skin Recovery of Healthy Volunteers","Evaluation of the Efficacy of a Topical Formulation Containing Acetyl Hexapeptide-37 on Skin Barrier Recovery of the Forearm After Controlled Damage Using the Tape-stripping Method","Inclusion Criteria:\n\n* healthy volunteers who gave written informed consent\n\nExclusion Criteria:\n\n* skin disease\n* skin damage on measurement sites\n* use of corticosteroids, antihistamines and immunomodulators a month prior the inclusion and during the trial\n* use of emollients three days prior the inclusion in the trial\n* non-adherence to the trial protocol\n* exposure to artificial and excessive natural ultraviolet (UV) radiation\n* pregnancy or breastfeeding\n* immunosuppression\n* allergic or irritant reactions to the constituents of the cream",{"count":21,"type":22},[58],"The goal of this clinical trial is to evaluate the efficacy of a topical peptide-based formulation containing Acetyl Hexapeptide-37 in promoting skin barrier recovery after controlled disruption in healthy adult participants.\n\nThe main questions it aims to answer are:\n\n* Does the peptide cream speed up the recovery of the skin barrier after it has been slightly damaged with tape-stripping method?\n* How does the peptide cream compare to a placebo (a cream with no active ingredient) in improving skin hydration and reducing redness?\n\nResearchers will compare the peptide cream to a placebo to assess its effects on skin barrier recovery\n\nParticipants will:\n\n* Undergo controlled disruption of the skin barrier on the volar forearm using the tape-stripping method.\n* One forearm will receive the peptide-based cream containing Acetyl Hexapeptide-37, while the other (contralateral) forearm will receive a placebo formulation.\n* Attend scheduled visits for non-invasive assessments of skin barrier function, including transepidermal water loss, skin hydration, and erythema",[61],"2026-06-15",{"date":88,"type":38},"2026-06-17",{"date":90,"type":38},"2026-06-01",{"date":92,"type":22},"2027-01",{"name":44,"class":45},{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":4,"eligibilityCriteria":100,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":19,"enrollmentInfo":101,"targetDuration":4,"studyType":56,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":108,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":112,"locationsCount":46},"100635110","study-of-a-peptide-creams-effect-on-the-facial-skin-barrier-using-a-side-by-side-comparison-100635110","NCT07548424","Study of a Peptide Cream's Effect on the Facial Skin Barrier Using a Side-by-Side Comparison","Evaluation of the Effect of a Topical Formulation Containing Acetyl Hexapeptide-37 on Objective Skin Barrier Parameters of the Face in a Randomized Controlled Split-Face Design","Inclusion Criteria:\n\n* healthy volunteers who gave written informed consent\n\nExclusion Criteria:\n\n* presence of active skin diseases or dermatological conditions\n* known allergy or hypersensitivity to any ingredient of the study products\n* pregnancy or breastfeeding\n* use of topical or systemic corticosteroids, immunosuppressive drugs, or antihistamines prior to or during the study",{"count":21,"type":22},[58],"The goal of this clinical trial is to evaluate whether a topical face cream containing the peptide Acetyl Hexapeptide-37 improves skin hydration and strengthens the skin barrier compared to a placebo cream in healthy adult participants. The study uses a split-face design, in which one side of the face is treated with the peptide cream and the other side with a placebo (a cream without the active ingredient).\n\nThe main questions it aims to answer are:\n\n* Does the peptide cream improve skin hydration and reduce transepidermal water loss compared to placebo?\n* Does the peptide cream affect skin erythema or cause irritation?\n* How do participants rate the comfort and tolerability of the peptide cream?\n\nResearchers will compare the treated and placebo sides of the face to assess differences in skin barrier function and tolerability.\n\nParticipants will:\n\n* Attend a baseline visit for assessment of facial skin parameters, including hydration, transepidermal water loss, and erythema\n* Apply the peptide cream to one side of the face and the placebo cream to the other side once daily for 4 weeks\n* Attend weekly follow-up visits for non-invasive skin measurements\n* Record any skin sensations (e.g., stinging, tightness) or adverse effects throughout the study",[105,106,107],"Skin Barrier Function","Skin Hydration","Topical Peptide Effects on Facial Skin Barrier Function",{"date":88,"type":38},{"date":110,"type":38},"2026-05-04",{"date":92,"type":22},{"name":44,"class":45},{"id":114,"slug":115,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":118,"acronym":4,"eligibilityCriteria":119,"healthyVolunteers":11,"sex":17,"minAge":120,"maxAge":18,"enrollmentInfo":121,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":123,"conditions":124,"keywords":126,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100642373","sleep-quality-and-biomarkers-in-adolescent-girls-with-anorexia-nervosa-100642373","NCT07644728","Sleep Quality and Biomarkers in Adolescent Girls With Anorexia Nervosa","Sleep Architecture, Inflammatory and Hormonal Biomarkers, Psychopathology, and Quality of Life in Adolescent Girls With Anorexia Nervosa: A Prospective Cohort Study","Inclusion Criteria:\n\n1. Female sex assigned at birth\n2. Age between 10 and 18 years (inclusive) at the time of study enrollment\n3. First-time diagnosis of anorexia nervosa according to ICD-10 criteria at the time of enrollment, including:\n\n   * Anorexia nervosa (F50.0)\n   * Atypical anorexia nervosa (F50.1)\n   * Eating disorder, unspecified (F50.9) with predominant restrictive or anorexic presentation\n4. Currently under the care of a child and adolescent psychiatrist at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia\n5. Enrolled in or eligible for the Day Hospital Program for Children and Adolescents at the Department of Psychiatry, KBC Split\n6. Ability to read and understand Croatian language sufficiently to complete self-report questionnaires\n7. Parent or legal guardian willing and able to provide written informed consent prior to any study procedure\n8. Participant willing and able to provide written assent prior to any study procedure\n9. Participant and parent\u002Fguardian willing to undergo all study procedures at both time points, including:\n\n   * Home polysomnography (NOX A1) at baseline and 12-month follow-up\n   * Completion of all self-report questionnaires at baseline and 12-month follow-up\n   * Fasting blood sampling at baseline and 12-month follow-up\n\nExclusion Criteria:\n\n1. Age younger than 10 years or older than 18 years at the time of enrollment\n2. Male sex assigned at birth\n3. Previous diagnosis of anorexia nervosa prior to current enrollment (i.e., recurrent or relapsing AN - this study enrolls first-diagnosis cases only)\n4. Anorexia nervosa currently in clinical remission at the time of enrollment\n5. Comorbid psychiatric diagnosis of any of the following:\n\n   * Intellectual disability (any severity, ICD-10: F70-F79)\n   * Autism spectrum disorder (ICD-10: F84)\n   * Schizophrenia spectrum or other psychotic disorder (ICD-10: F20-F29)\n   * Bipolar affective disorder, any type (ICD-10: F31)\n   * Substance use disorder, any substance (ICD-10: F10-F19)\n6. Severe or chronic somatic illness documented in medical history, including but not limited to:\n\n   * Central nervous system disorders (epilepsy, acquired brain injury, neurodegenerative disease, ICD-10: G00-G99)\n   * Chronic inflammatory or autoimmune disease (e.g., inflammatory bowel disease, systemic lupus erythematosus, rheumatoid arthritis)\n   * Primary endocrine disorder independent of AN (e.g., primary hypothyroidism, type 1 or type 2 diabetes mellitus, congenital adrenal hyperplasia)\n   * Active or history of malignancy\n   * Chronic renal or hepatic disease\n7. Use of any medication known to significantly alter sleep architecture or inflammatory biomarker levels that was initiated prior to study enrollment and is unrelated to the study treatment program, including:\n\n   * Benzodiazepines or z-drugs (zopiclone, zolpidem)\n   * Antipsychotic medications\n   * Systemic corticosteroids\n   * Immunosuppressive agents\n   * Melatonin or melatonin receptor agonists Medications initiated as part of the Day Hospital treatment program after enrollment will be documented and included as covariates in statistical analyses and do not constitute an exclusion criterion.\n8. Presence of an active somatic condition at the time of enrollment requiring acute inpatient medical treatment (e.g., severe electrolyte imbalance requiring intravenous correction, acute cardiac arrhythmia) that would preclude safe participation in the Day Hospital Program\n9. Physical or cognitive inability to cooperate with home polysomnography device placement or self-report questionnaire completion, as judged by the treating child and adolescent psychiatrist\n10. Simultaneous participation in another interventional clinical trial that could influence sleep parameters, nutritional status, inflammatory markers, or psychiatric outcomes.\n11. Absence of written informed consent from parent or legal guardian, or absence of written assent from the participant","10 Years",{"count":122,"type":22},25,"The purpose of this observational study is to systematically evaluate how a 12-month multimodal psychiatric treatment program affects sleep quality, inflammatory and hormonal biomarkers, eating disorder psychopathology, and health-related quality of life in adolescent girls (aged 10-18 years) diagnosed with anorexia nervosa.\n\nThe main questions it aims to answer are:\n\n* Do adolescent girls with anorexia nervosa have measurable changes in sleep patterns (total sleep time, sleep efficiency, REM sleep, deep sleep) compared to age- and sex-matched published values, and do these improve after 12 months of psychiatric treatment?\n* Are specific body markers (like NLR, CRP, vitamin D, and lipid profile) linked to how severe sleep problems, eating disorder symptoms, and treatment results are in this group?\n* To assess these outcomes, researchers will compare participants' baseline measurements to their own 12-month follow-up measurements to determine whether multimodal psychiatric treatment produces clinically meaningful improvements in sleep architecture, biomarker profiles, psychopathology, psychological flexibility, and quality of life.\n\nParticipants will:\n\n* Take-home sleep recordings with a wireless device (NOX A1) in their usual environment at the start and after 12 months of treatment.\n* Complete validated self-report questionnaires assessing sleep quality (PSQI), daytime sleepiness (ESS-CHAD for children and adolescents), eating disorder symptoms (EDE-Q), depression, anxiety, and stress (DASS-21), psychological flexibility (AFQ-Y8), and health-related quality of life (KIDSCREEN-52) at baseline and 12-month follow-up.\n* Give blood samples at the start and after 12 months for testing of inflammation markers, hormone levels, lipids, and anthropometric measurements.\n* Take part in a Day Hospital Program at the Department of Psychiatry, University Hospital of Split (KBC Split), Croatia, which includes Acceptance and Commitment Therapy, Cognitive Behavioral Therapy, individual counselling, family work, and medication if needed.",[125],"Anorexia Nervosa",[125,127,128,129,130,131,132],"Sleep Quality","Adolescents, Female","Eating Behaviour","Mental Health","Quality of life","Inflammatory markers","NOT_YET_RECRUITING","2026-06-08",{"date":136,"type":38},"2026-06-12",{"date":138,"type":22},"2026-05-30",{"date":140,"type":22},"2029-12-31",{"name":44,"class":45},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":16,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":56,"phases":150,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":46},"100614968","glycyrrhetinic-acid-and-acute-irritant-dermatitis-100614968","NCT07286487","Glycyrrhetinic Acid and Acute Irritant Dermatitis","Effects of Glycyrrhetinic Acid on Human Skin in an Acute Irritant Contact Dermatitis Model","Inclusion Criteria:\n\n* Healthy adult participants aged 18 years or older, of any sex.\n* Intact, healthy skin at the test sites.\n* No use of systemic or topical corticosteroids, immunomodulators, or antihistamines within the previous three months.\n* No use of topical emollients on the test sites within the previous seven days.\n\nExclusion Criteria:\n\n* Pregnant women, women suspected of being pregnant, and breastfeeding women.\n* Non-compliance with the study protocol.\n* Voluntary withdrawal or personal decision not to continue participation.",{"count":21,"type":22},[58],"Irritant dermatitis is one of the most common inflammatory skin disorders, caused by exposure to external substances that induce inflammation and immune activation. Standard management includes avoidance of irritants, restoration of the skin barrier using emollients, and the application of anti-inflammatory drugs such as topical corticosteroids. However, due to the risks associated with long-term corticosteroid use, there is an interest in developing emollient formulations enriched with bioactive compounds possessing anti-inflammatory properties. Among those promising compounds is glycyrrhetinic acid.\n\n18β-Glycyrrhetinic acid, a bioactive component of licorice root extract, exhibits potent anti-inflammatory and antioxidant effects. Topical application has demonstrated beneficial outcomes in conditions such as atopic dermatitis, acne, pruritus, and UVB-induced skin damage. Its proposed mechanisms of action include inhibition of key inflammatory enzymes (COX, 5-LOX, iNOS) and promotion of skin regeneration through stimulation of aquaporin-3 expression and enhancement of epidermal turnover.\n\nTopical application of formulations containing 18β-glycyrrhetinic acid will improve skin parameter disturbances caused by irritation induced with sodium lauryl sulfate.\n\nThis study aims to evaluate the effects of 18β-glycyrrhetinic acid on human skin parameters in an acute irritant dermatitis model induced by sodium lauryl sulfate, providing further insight into its potential role as an anti-inflammatory and barrier-restoring agent.\n\nFunding:\n\nFunded by the European Union - NextGenerationEU. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Commission. Neither the European Union nor the European Commission can be held responsible for them.",[153],"Irritant Contact Dermatitis","2026-02-12",{"date":156,"type":38},"2026-02-13",{"date":158,"type":22},"2026-03-01",{"date":160,"type":22},"2027-04-25",{"name":44,"class":45},{"id":163,"slug":164,"hasResults":11,"nctId":165,"briefTitle":166,"officialTitle":167,"acronym":4,"eligibilityCriteria":168,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":169,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":171,"conditions":172,"keywords":174,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":183,"lastUpdatePostDateStruct":184,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":46},"100617155","maternal-sleep-and-lifestyle-metabolic-health-and-perinatal-outcomes-in-gestational-diabetes-100617155","NCT07314944","Maternal Sleep and Lifestyle, Metabolic Health, and Perinatal Outcomes in Gestational Diabetes","Integrated Assessment of Sleep, Mental Health, Lifestyle Behaviors, Metabolic Markers, and Perinatal Outcomes in Women With Gestational Diabetes Mellitus: A Prospective Cohort Study","Inclusion Criteria:\n\n* Pregnant women aged 18 years or older\n* New diagnosis of gestational diabetes mellitus (GDM) according to IADPSG criteria\n* Gestational age 24-34 weeks at enrollment\n* Able to complete study questionnaires (sleep, anxiety, eating behavior, lifestyle)\n* Able to provide informed consent\n* For participants in the home-monitoring pathway: ability to use a smartphone and the FreeStyle Libre device\n\nExclusion Criteria:\n\n* Pre-existing type 1 or type 2 diabetes mellitus\n* Current preeclampsia or major obstetric complications at enrollment\n* Major psychiatric disorders interfering with participation\n* Chronic use of sedatives or anxiolytic medications\n* Inability to complete questionnaires\n* Planned delivery outside the study's hospital network\n* Any condition judged by clinicians to interfere with participation or data reliability",{"count":170,"type":22},100,"The goal of this observational study is to learn how sleep quality, mental health, lifestyle behaviors, and metabolic markers are related to glucose control and pregnancy outcomes in women with gestational diabetes mellitus (GDM). The main questions it aims to answer are:\n\n* Do differences in sleep quality, anxiety levels, and eating behaviors relate to differences in glycemic control in women with GDM?\n* Are maternal metabolic markers (such as glucose, liver enzymes, and lipid levels) associated with perinatal outcomes such as birth weight, cesarean delivery, and neonatal complications?\n* To compare women who undergo short inpatient glucose monitoring with women who undergo home-based digital glucose monitoring to see if the mode of monitoring is related to differences in sleep, mental health, metabolic profiles, or perinatal outcomes.\n\nParticipants will:\n\n* Complete questionnaires on sleep, anxiety, lifestyle, and eating behaviors\n* Undergo routine laboratory testing, including metabolic and blood markers.\n* Have glucose monitored either during a short hospital stay or through home use of the FreeStyle Libre sensor.\n* Be followed from GDM diagnosis (24-34 weeks) until delivery to assess maternal and newborn outcomes",[173],"Gestational Diabetes",[175,127,176,130,177,178,179,180,181,182],"Gestational Diabetes Mellitus","Anxiety","Eating Behavior","Lifestyle Factors","Physical Activity","Metabolic Markers","Glycemic Control","Perinatal Outcomes","2025-12-30",{"date":185,"type":38},"2026-01-02",{"date":187,"type":38},"2025-11-01",{"date":189,"type":22},"2030-01-01",{"name":44,"class":45},{"id":192,"slug":193,"hasResults":11,"nctId":194,"briefTitle":195,"officialTitle":196,"acronym":197,"eligibilityCriteria":198,"healthyVolunteers":11,"sex":54,"minAge":199,"maxAge":200,"enrollmentInfo":201,"targetDuration":4,"studyType":56,"phases":203,"briefSummary":204,"conditions":205,"keywords":208,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":218,"completionDateStruct":220,"leadSponsor":222,"locationsCount":46},"100594260","remission-of-type-2-diabetes-with-lifestyle-intervention-100594260","NCT07017127","Remission of Type 2 Diabetes With Lifestyle Intervention","Remission of Type 2 Diabetes With Mediterranean Diet, Physical Activity and Psychological Support: a Randomized Clinical Trial","REMeDI2ME","Inclusion Criteria:\n\n* type 2 diabetes diagnosis\n* incident cases or diagnosed not more than 7 years ago\n* body mass index of 27-45 kg\u002Fm²\n\nExclusion Criteria:\n\n* mobility restriction\n* use of mobility aids\n* insulin therapy\n* HbA1c \\>12%\n* TSH \\>10 mU\u002FL\n* heart failure (NYHA III, NYHA IV)\n* use of obesity pharmacotherapy (orlistat, GLP-1 receptor agonists, GLP-1\u002FGIP dual agonists) for less than 6 months\n* weight loss greater than 5 kg in the last 6 months\n* chronic kidney disease and estimated glomerular filtration rate \\\u003C30 ml\u002Fmin\u002F1.73 m2\n* active treatment of proliferative diabetic retinopathy with anti-VEGF\n* heart attack or stroke in the past 1 year\n* active malignant disease diagnosed in the past 1 year\n* eating disorders\n* pregnancy or pregnancy planning\n* substance abuse\n* learning disabilities\n* acute episode of severe depression\n* current use of antipsychotics\n* food allergy","20 Years","69 Years",{"count":202,"type":22},120,[58],"The goal of this clinical trial is to achieve diabetes type 2 (DM2) remission using intensive lifestyle intervention.\n\nThe main questions it aims to answer are:\n\n* Does intensive lifestyle intervention (including Mediterranean diet with a caloric deficit, daily physical activity, increase in stress resilience and group support) lead to DM2 remission (HbA1c\\\u003C6.5%, without medications)\n* Can intensive lifestyle intervention (including Mediterranean diet with a caloric deficit, daily physical activity, increase in stress resilience and group support) result to weight loss of \\>15 kg\n* Does intensive lifestyle intervention result in any side effects (secondary outcome)\n\nResearchers will compare intensive lifestyle intervention to the usual clinical care (control group).\n\nParticipants in the experimental group will:\n\n* eat Mediterranean diet with a caloric deficit\n* perform daily physical activity\n* increase their stress resilience with psychosocial support of the group\n* enroll weekly in individual and group counseling and workshops for 6 months, following with 1.5 years of follow-up",[206,207],"Diabetes Mellitus Type 2","Obese Diabetics",[209,210,211,212,213,214],"diabetes remission","Mediterranean diet","physical activity","stress","weight loss","healthy lifestyle","2025-06-10",{"date":217,"type":38},"2025-06-12",{"date":219,"type":38},"2025-05-01",{"date":221,"type":22},"2027-12-17",{"name":44,"class":45},{"id":224,"slug":225,"hasResults":11,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":230,"targetDuration":4,"studyType":56,"phases":231,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":235,"lastUpdatePostDateStruct":236,"startDateStruct":238,"completionDateStruct":240,"leadSponsor":242,"locationsCount":46},"100592501","boosting-cpap-use-in-adults-with-severe-sleep-apnea-role-of-motivation-and-psychological-factors-100592501","NCT06994247","Boosting CPAP Use in Adults With Severe Sleep Apnea: Role of Motivation and Psychological Factors","Impact of Phenotypic and Psychological Characteristics and a Motivational Telephone Intervention on Continuous Positive Airway Pressure (CPAP) Adherence in Patients With Severe Obstructive Sleep Apnea","Inclusion Criteria:\n\n* Participants aged 18 years or older\n* Diagnosis of severe obstructive sleep apnea (OSA), defined as AHI ≥30\n* Signed informed consent for participation in the study\n* Adequate physical and psychological capacity to participate in the intervention and complete questionnaires\n* Patients who are initiating CPAP therapy at the Sleep Medicine Center, University of Split School of Medicine\n* Availability for follow-up over a three-month period\n\nExclusion Criteria:\n\n* Presence of central sleep apnea or other primary sleep disorders\n* Cognitive impairment or psychiatric conditions that may hinder the ability to follow instructions or complete questionnaires\n* Previous experience with CPAP therapy prior to study enrollment\n* Significant comorbidities (e.g. unstable cardiovascular disease, advanced pulmonary disease) that may interfere with study outcomes\n* Pregnancy\n* Inability to participate in follow-up assessments or be contacted by telephone",{"count":170,"type":22},[58],"The goal of this randomized prospective clinical trial is to examine whether phenotypic traits, psychological characteristics, assessed by STAI (engl. The State-Trait Anxiety Inventory) and IPIP50S (engl. International Personality Item Pool) questionnaires, and patients' self-efficacy, assessed by SEMSA (engl. Self-Eficacy Measure for Sleep Apnea) questionnaire, are associated with CPAP adherence after three months of use. The study also evaluates whether a motivational phone call one month after therapy initiation improves CPAP adherence at the three-month follow-up. The main questions it aims to answer are:\n\n* Are phenotypic and psychological traits associated with adherence to CPAP therapy after 3 months of treatment?\n* Can a single motivational telephone intervention, one month after initiating CPAP therapy, significantly improve CPAP adherence at the three-month follow-up compared to no intervention? Researchers will compare patients who receive a phone call to those who do not, to see if this simple intervention leads to better CPAP adherence after three months of use.\n\nParticipants will:\n\n* Undergo polysomnography before starting CPAP therapy,\n* Complete three questionnaires (IPIP50S, STAI, SEMSA) before starting CPAP therapy,\n* Be randomly assigned to either receive a motivational phone call one month after starting CPAP therapy or to a control group without any phone call,\n* Be invited for a follow-up after three months of CPAP use to download and analyze CPAP adherence data from their CPAP devices.",[234],"Obstructive Sleep Apnea (OSA)","2025-05-28",{"date":237,"type":38},"2025-05-29",{"date":239,"type":38},"2025-04-14",{"date":241,"type":22},"2026-04-01",{"name":44,"class":45},{"id":244,"slug":245,"hasResults":11,"nctId":246,"briefTitle":247,"officialTitle":248,"acronym":4,"eligibilityCriteria":249,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":250,"enrollmentInfo":251,"targetDuration":4,"studyType":56,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":133,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":261,"leadSponsor":263,"locationsCount":4},"100532166","the-impact-of-selective-vitamin-d-receptor-activation-on-clinical-outcomes-in-septic-patients-100532166","NCT06209268","The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients","The Impact of Selective Vitamin D Receptor Activation on Clinical Outcomes in Septic Patients -a Randomised Placebo Controlled Trial","Inclusion Criteria:The participants of this study will be patients:\n\n* admitted as sepsis in a medical ICU. The including criteria for sepsis will be defined according The Third International Consensus Definitions for Sepsis and Septic Shock. The sepsis will be defined as suspected infection with SOFA score\\>=2.\n* The subgroup of participants with septic shock will be defined as sepsis with vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol\u002FL despite adequate fluid resuscitation.\n\nExclusion Criteria:\n\n* total serum calcium ≥2.60 mmol\u002FL,\n* significant chronic end stage heart, kidney or liver disease\n* active treatment with corticosteroids or cytotoxic drugs\n* autoimmune diseases\n* malignancies\n* cachexia\n* previously been on active vitamin D therapy the last four months prior to the study period.","99 Years",{"count":252,"type":22},90,[58],"Sufficient serum levels of vitamin D are important for immune system regulation with protective effect against severe infection and overactivated inflammatory response in sepsis. It is also not clear what level of vitamin D in the blood would be the trigger for vitamin D administration. A more selective approach to VDR activation than cholecalciferol could have a more significant role in the clinical outcomes of patients with sepsis. A study demonstrated that low baseline serum level of vitamin D receptor (VDR) was associated with a high incidence of 28-day mortality and negatively correlated with lactate, C-reactive protein, APACHE II SOFA scores, and disease severity among patients with sepsis in an ICU setting.\n\nThe role of selective vitamin D receptor activation agents (paricalcitol or maxacalcitol) was not studied in septic patients, despite its anti-inflammatory and immunomodulatory properties. Vitamin D analogs have different effects on nuclear VDRs than does calcitriol, through different response elements in various target genes, so it is possible that their effect on a patient with sepsis will be more effective than cholecalciferol. As distribution of VDRs is ubiquitous in many organs and tissues, selective VDR activation with paricalcitol may have beneficial effects in preserving organs functionality and modulating the immune response in sepsis.\n\nHypotheses\n\n1. The immunoregulatory, anti-inflammatory, and anti-oxidative properties of selective vitamin D receptor activator paricalcitol would result in improvement of inflammatory, endothelial function, and antioxidative parameters and clinical outcomes in groups of septic patient admitted to ICU.\n2. The baseline septic patient serum 25(OH) D3 levels at admission time in ICU have influence on clinical outcomes as well as on inflammatory, endothelial function, and antioxidative parameters.\n3. The inflammatory, endothelial function, and antioxidative parameters measured at ICU admission time have significant impact on clinical outcomes in septic patients.\n\nThe aim\n\nThe main objective of study is to test hypothesis that that selective activator of vitamin D receptors paricalcitol will improve outcomes of septic patient admitted in ICU. The study aims to investigate the effects of paricalcitol on clinical outcomes, inflammatory markers, organ dysfunction, endothelial function, vascular morphology, coagulation markers, and haemodynamic parameters.\n\nThe additional objectives of the study are to test hypothesis that septic patient serum 25(OH)vitamin D3 have impact on inflammatory, endothelial function, and antioxidative parameters including protein carbonylation; and to test hypothesis that these markers and clinical outcomes are interconnected with significant impact on clinical outcomes.",[256],"Sepsis","2024-12-04",{"date":259,"type":38},"2024-12-06",{"date":219,"type":22},{"date":262,"type":22},"2026-02-01",{"name":44,"class":45},{"id":265,"slug":266,"hasResults":11,"nctId":267,"briefTitle":268,"officialTitle":268,"acronym":269,"eligibilityCriteria":270,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":271,"enrollmentInfo":272,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":274,"conditions":275,"keywords":278,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":286,"lastUpdatePostDateStruct":287,"startDateStruct":289,"completionDateStruct":291,"leadSponsor":293,"locationsCount":46},"100408866","investigation-of-subclinical-markers-of-multiple-sclerosis-100408866","NCT04604041","Investigation of Subclinical Markers of Multiple Sclerosis","SUBCLIN-MS","Inclusion Criteria:\n\n* Subjects with a documented diagnosis of relapsing-remitting MS according to the Mc Donald criteria (2005) and with EDSS achievement of 0-3.5 according to the modified Kurtzke's EDSS (Expanded disability status scale) for the assessment of neurological function and incapacity of patients with multiple sclerosis\n\nExclusion Criteria:\n\n* Patients with metals in the body (e.g. pacemaker, dentures)\n* Patients with new pregnancies (verbally confirmed)\n* Patients with new head trauma\n* Subjects unwilling to sign a consent or follow study procedures","65 Years",{"count":273,"type":22},50,"Transcranial magnetic stimulation (TMS) studies reported consistent and substantial impairments in the central nervous system (CNS) in multiple sclerosis (MS). Studies of peripheral nervous system (PNS) function comprising electromyoneurography (EMNG) reported impairments of the PNS in MS that were less pronounced and inconsistent. Neurophysiological studies are generally small and cross-sectional and with the poor grouping of MS patients according to MS type.\n\nThe objective of the study is to investigate clinical, neurophysiological, and immunological markers in relapsing-remitting MS patients, and in patients with relapsing-remitting MS treated with immunomodulation. The results of the study may contribute to a better understanding of the pathophysiology of multiple sclerosis and can provide guidance in the diagnosis and treatment of patients with relapsing-remitting MS.",[276,277],"Multiple Sclerosis","Relapsing Remitting Multiple Sclerosis",[279,280,281,282,283,284,285],"multiple sclerosis","relapsing remitting","TMS","Cytometry","ELISA","corticosteroids","immunomodulation","2023-09-28",{"date":288,"type":38},"2023-10-02",{"date":290,"type":38},"2020-11-23",{"date":292,"type":22},"2028-12-31",{"name":44,"class":45},{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":298,"acronym":4,"eligibilityCriteria":299,"healthyVolunteers":11,"sex":54,"minAge":18,"maxAge":4,"enrollmentInfo":300,"targetDuration":4,"studyType":56,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":46},"100310425","cauterization-versus-brin-glue-for-conjunctival-autografting-in-primary-pterygium-surgery-100310425","NCT03321201","Cauterization Versus fibrin Glue for Conjunctival Autografting in Primary Pterygium Surgery","Inclusion criteria:\n\n* adults (older than 18 years of age)\n* both sexes\n* primary nasal pterygia ˃4 mm, which tends to increase, including patients with reduced visual acuity, chronic inflammation, cosmetic reasons\n* if the patients had a bilateral pterygium, only one eye will be operated\n\nExclusion criteria:\n\n* connective tissue disease\n* prior eye surgery\n* chronic use of topical drugs (anti-glaucoma drugs)",{"count":301,"type":22},164,[58],"Pterygium is a noncancerous growth of the conjunctival tissue over the cornea. It is a progressive disease that may lead to visual impairment in advanced stages, as well as restriction of ocular motility, chronic inflammation and cosmetic concerns. Surgical removal is the treatment of choice, but recurrence of pterygium is a frequent problem. In this randomized controlled cauterization will be compared with fibrin glue for conjunctival autografting in primary pterygium surgery.",[305],"Pterygium of Conjunctiva and Cornea","2022-11-01",{"date":308,"type":38},"2022-11-02",{"date":310,"type":38},"2018-05-08",{"date":312,"type":22},"2026-12-31",{"name":44,"class":45},""]